

Dear Readers,

Greetings of the Season,

We had launched ijopp in October 2008 in the APTI convention and I feel proud to announce that we have successfully completed 5 years. Initially there was a problem of number of articles being submitted but slowly we started getting good number of articles from the Pharmacy Practice researchers although the quality of the articles needs further improvement.

As you are aware that, each year Association of Pharmaceutical Teachers of India (APTI) confers two awards for the best research articles published in ijopp in the areas of Clinical Pharmacy and Community Pharmacy.

The editorial team of ijopp congratulates Mr. Showande SJ and Olaifa & Mr. Stejin Jacob et.al., for being selected for The Late Smt. V.G. Yeole Memorial Award for Community Pharmacy and Shri. Ishwar N. Hukkeri Memorial Award for Clinical Pharmacy respectively. The details of the two awards for the year 2012 are as follows.

1. Late Smt.V.G. Yeole Memorial Award for Best Research Article in Community Pharmacy

Community Pharmacist's Involvement in the Ordering and Interpretation of Laboratory Tests in two South-western States In Nigeria

Showande SJ, Olaifa OA- (ijopp Oct-Dec 2012;5(4):76-83.)

2. Shri. Ishwar N. Hukkeri Memorial Award for Clinical Pharmacy

Pharmacoeconomic Analysis of Asthma in Pediatric Patients in Tertiary Care Hospital in Kerala.

Stejin J, Kishor KV, Nandha KN, Srinivasan A, Arul PKC, Kannan S - (ijopp Jul-Sep 2012;5(3):25-29)

As you are all aware of, the office bearers of APTI have changed after APTI 2013 elections and there is also a slight change in the editorial team of ijopp from October 2013.

Recently, there are quite a few amendments happening w.r.t. clinical trials in India. The conduct of clinical trials in India is getting stringent. To ensure that clinical trials are done legally and safety of participants is given utmost importance, the ministry of health and family welfare has said that clinical trials can only be carried out in accredited centers and also the principal investigator and the ethics committee should also be accredited, only then the trials will be approved. Phase I-IV of all new drugs developed/to be marketed in India will be need to be carried out in India. Amendments to the drugs and cosmetics act, pending before Parliament, have penal provisions for failure to comply with norms to conduct clinical trials.

The stricter guidelines are sure to increase the credibility and integrity of clinical trial data and helps increase compliance with drugs and cosmetics regulations.

Readers who can give greater insight in to this current scenario in India are invited to contribute the same through Letters to the Editor.

Hope all of you have great learning and enjoyable time in the APTI convention 2013.

Dr. Shobha Rani R Hiremath

Editor-in-Chief